


Application No. 09/925,224  
September 25, 2002  
Page 6

Clean Copy of the Pending Claims

4. A compound having the general structure:



wherein R<sub>1</sub>, R<sub>7</sub> and R<sub>8</sub> are independently selected from the group consisting of H, halo, haloalkyl and hydroxy; and


R<sub>3</sub> is hydroxy or -OCONH<sub>2</sub>.

5. The compound of claim 4 wherein R<sub>7</sub> and R<sub>8</sub> are H;

R<sub>1</sub> is H or F; and

R<sub>3</sub> is hydroxy or -OCONH<sub>2</sub>.

14. A pharmaceutical composition comprising a compound selected from the group consisting of




wherein R<sub>7</sub>, R<sub>8</sub> and R<sub>9</sub> are independently selected from the group consisting of H, halo, alkyl, haloalkyl and hydroxy;

R<sub>3</sub> is hydroxy or -OCONH<sub>2</sub>; and

a pharmaceutically acceptable carrier.


15. The composition of claim 14 wherein said compound has the general structure



Application No. 09/925,224  
September 25, 2002  
Page 7

wherein R<sub>9</sub> is selected from the group consisting of H, halo, haloalkyl and hydroxy; and R<sub>3</sub> is hydroxy or -OCONH<sub>2</sub>.

16. The composition of claim 15 wherein R<sub>9</sub> is halo.
17. The composition of claim 15 wherein R<sub>9</sub> is H or F; and R<sub>3</sub> is -OCONH<sub>2</sub>.
18. The composition of claim 15 wherein R<sub>9</sub> is H or F; and R<sub>3</sub> is hydroxy.
19. A compound having the general structure:



wherein R<sub>1</sub>, R<sub>7</sub>, R<sub>8</sub>, R<sub>9</sub> and R<sub>10</sub> are independently selected from the group consisting of H, halo, alkyl, haloalkyl, -NR<sub>5</sub>R<sub>6</sub>, hydroxy, and alkoxy;

R<sub>2</sub> is F or Cl;  
R<sub>3</sub> is hydroxy or -OCONH<sub>2</sub>; and  
R<sub>5</sub> and R<sub>6</sub> are independently C<sub>1</sub>-C<sub>4</sub> alkyl.

20. The compound of claim 19 wherein R<sub>1</sub> and R<sub>7</sub> are independently selected from the group consisting of H, halo, alkyl, haloalkyl, and hydroxy;  
R<sub>2</sub> is F;  
R<sub>3</sub> is hydroxy or -OCONH<sub>2</sub>; and R<sub>5</sub>, R<sub>9</sub> and R<sub>10</sub> are H.

Application No. 09/925,224  
September 25, 2002  
Page 8

21. The compound of claim 19 wherein

R<sub>1</sub> and R<sub>8</sub> are independently selected from the group consisting of H, halo, alkyl, haloalkyl, and hydroxy;

R<sub>2</sub> is F;

R<sub>3</sub> is hydroxy or -OCONH<sub>2</sub>; and

R<sub>7</sub>, R<sub>9</sub> and R<sub>10</sub> are H.

22. The compound of claim 19 wherein

R<sub>1</sub> is selected from the group consisting of H, halo, alkyl, haloalkyl, and hydroxy;

R<sub>2</sub> is F;

R<sub>3</sub> is hydroxy or -OCONH<sub>2</sub>; and

R<sub>7</sub>, R<sub>8</sub>, R<sub>9</sub> and R<sub>10</sub> are H.

23. The compound of claim 22 wherein

R<sub>1</sub> is selected from the group consisting of H, F, Cl, CF<sub>3</sub>, and hydroxy.

24. The compound of claim 23 wherein

R<sub>1</sub> is F.

25. A pharmaceutical composition comprising the compound of claim 19 and a pharmaceutically acceptable carrier.

26. A pharmaceutical composition comprising the compound of claim 22 and a pharmaceutically acceptable carrier.